“…Recently, glycosidase inhibitors have gained considerable clinical relevance [18][19][20][21] and several glycomimetics such as zanamivir ® , miglustat ® , migalastat ® , voglibose ® , and acarbose ® reached the market. The selective hydrolysis of glycosidic bonds in carbohydrates and glycoconjugates is indeed involved in a plethora of key cellular processes in biological systems [22][23][24][25], and thus targeting glycosidases holds great potential for the treatment of many diseases such as type 2 diabetes [25][26][27], viral infection [21,[27][28][29][30][31], tumor metastasis [21,27,32,33], or medical diagnosis [34].…”